Pfizer, COVID-19
Pfizer v Moderna COVID vaccine patents battle to go to appeal in UK
Pfizer and Moderna's legal battle over their rival COVID-19 vaccines will continue after London's High Court on Wednesday gave Pfizer permission to take the case to the Court of Appeal. Pfizer and its German partner BioNTech sued Moderna in London in September 2022,
Pfizer/BioNTech Covid-19 Vaccine Adapted for KP.2 Strain Gets Canada Approval
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing opportunities, strengthen advisor-client relationships and build investor experiences. Learn More. Back To Top
Pfizer's updated COVID-19 vaccine approved, Health Canada says
Pfizer-BioNTech's updated vaccine to protect against a recently circulating variant of COVID-19 is authorized, Health Canada said on Tuesday.
Health Canada approves Pfizer's updated COVID-19 vaccine, manufacturer says
Pfizer Canada says Health Canada has approved its updated COVID-19 vaccine that protects against one of the most recently circulating variants of the virus.
Pfizer Canada and BioNTech Receive Health Canada Approval of Omicron KP.2 Variant Adapted COVID-19 Vaccine
Omicron KP.2 variant adapted vaccine COMIRNATY is now authorized in Canada for individuals 6 months of age and older. It is expected to be available in Canada in the coming weeks. -- The updated COVID-19 vaccine is tailored to the KP.
Pfizer Is Rising Past Covid-19
Pfizer Inc. ( PFE, Financial) rose to prominence during the Covid-19 pandemic for its rapid development of a vaccine and ...
kalkinemedia35m
Pfizer Shares Experience Minor Decline
Headlines,Pfizer's stock price decreased by 0.8% during Wednesday's trading session.,Shares traded at a low of $29.23 before ...
labiotech7h
How Pfizer’s decision in the ’90s cost them a stronghold in the GLP-1 market
Discover an untold biotech story and find out how Pfizer missed an opportunity in the GLP-1 market because of an exit in the ...
Pfizer Inc. (PFE): Why Are Street Analysts Bullish On This Wide Moat Stock Now?
We recently compiled a list of the 8 Best Wide Moat Stocks to Buy According to Analysts. In this article, we are going to ...
Pfizer Inc. stock outperforms competitors on strong trading day
The stock's rise snapped a five-day losing streak.
Pfizer: Undervalued Healthcare Leader Poised For Further Recovery
Pfizer's stock underperformed its healthcare peers since PFE topped out in late July 2024. Click here to find out why I ...
bovnews3h
Daiwa Securities Issues Outper form Rating for Pfizer Inc (PFE) Stock
Pfizer Inc (PFE) stock saw a modest uptick, ending the day at $29.5 which represents a slight increase of $0.19 or 0.65% from the prior close of $29.31. The stock opened at $29.25 and touched a low of ...
Pfizer Inc. stock outperforms competitors despite losses on the day
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Is Pfizer's 5.7% Dividend Yield Worth the Risk?
Pharmaceutical giant Pfizer ( PFE 2.73%) stands out in this context. The company currently offers a mouthwatering 5.7% ...
Pfizer Unusual Options Activity
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...
Pfizer pushing BRAF lung cancer mutation testing to grow market for Braftovi
Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug ...
Zacks.com on MSN1d
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...